» Articles » PMID: 20403575

New Type of Human Blood Stem Cell: a Double-edged Sword for the Treatment of Type 1 Diabetes

Overview
Journal Transl Res
Publisher Elsevier
Specialty Pathology
Date 2010 Apr 21
PMID 20403575
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes (T1D) is an autoimmune disease caused by an autoimmune destruction of pancreatic islet insulin-producing cells. Autoimmunity and shortage of insulin-producing cells are 2 key issues for the treatment of T1D. To cure T1D in a comprehensive manner, both issues need to be addressed simultaneously. Not only must the islet cells be replaced, the patient's immune system also must be dealt with. Regulatory T cells (Tregs) play a crucial role in maintaining homeostasis and self-tolerance through their inhibitory impacts on autoreactive effector T cells. We identified a novel type of stem cells from human umbilical cord blood, designated cord blood stem cells (CB-SC), which may be able to address immune modulation of the autoimmune process and allow for beta-cell replacement. We are the first group using CB-SC to correct functional defects of CD4(+)CD62L(+) Tregs, leading to a reversal of overt diabetes in an autoimmune-caused diabetic NOD mouse model. Notably, treatment with CB-SC-modulated CD4(+)CD62L(+) Tregs (mCD4CD62L Tregs) simultaneously can overcome the autoimmunity via systemic and local immune modulations and the shortage of insulin-producing cells via stimulating the beta-cell regeneration. These new stem cells will offer a promising avenue for the development of powerful autologous therapeutic products for prevention and reversal of T1D.

Citing Articles

The efficiency of stem cell differentiation into functional beta cells for treating insulin-requiring diabetes: Recent advances and current challenges.

Luo Y, Yu P, Liu J Endocrine. 2024; 86(1):1-14.

PMID: 38730069 DOI: 10.1007/s12020-024-03855-8.


Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results.

Mesples A, Majeed N, Zhang Y, Hu X Med Sci Monit. 2013; 19:852-7.

PMID: 24121994 PMC: 3808238. DOI: 10.12659/MSM.889525.


Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial.

Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H BMC Med. 2013; 11:160.

PMID: 23837842 PMC: 3716981. DOI: 10.1186/1741-7015-11-160.


Stem cell educator therapy and induction of immune balance.

Zhao Y Curr Diab Rep. 2012; 12(5):517-23.

PMID: 22833322 DOI: 10.1007/s11892-012-0308-1.


Autologous cord blood harvesting in North Eastern Italy: ethical questions and emerging hopes for curing diabetes and celiac disease.

Parco S, Vascotto F Int J Gen Med. 2012; 5:511-6.

PMID: 22807638 PMC: 3396118. DOI: 10.2147/IJGM.S31977.